Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

News releases from Adaptimmune Therapeutics plc

< Previous 1 2 3 4 5 6 Next >
Adaptimmune Announces Clinical Responses across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation SURPASS Trial
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies
Tickers ADAP RHHBY
From GlobeNewswire News Releases
Adaptimmune Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Showing Clinical Benefit
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune Reports Second Quarter Financial Results and Business Update
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune to Report Q2 2021 Financial Results and Business Update on Monday, August 9, 2021
Tickers ADAP
From GlobeNewswire News Releases
Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune’s Phase 2 SPEARHEAD-1 Trial
Tickers ADAP
From GlobeNewswire News Releases
First Preclinical Data from Adaptimmune’s Mesothelin HiT Program at ASGCT Demonstrate Antigen-specific Tumor Cell Killing in vitro and Complete Tumor Regression in an Animal Model
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune Reports First Quarter Financial Results and Business Update
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune to Report Q1 2021 Financial Results and Business Update on Thursday, May 6, 2021
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune Reports Fourth Quarter / Full Year 2020 Financial Results and Business Update
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune to Report Fourth Quarter/ Full Year 2020 Financial Results and Business Updates on Thursday, February 25, 2021
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune to Showcase Market Potential for SPEAR T-cell Portfolio and Pipeline with Multiple Cell Therapy Platforms During Virtual Investor Day
Tickers ADAP
From GlobeNewswire News Releases
Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 94% Presented at CTOS
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune to Host Virtual Investor Day on Friday, November 20th
Tickers ADAP
From GlobeNewswire News Releases
Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, Presented at SITC
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune Reports Q3 Financial Results and Business Update
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune to Report Q3 Financial Results and Business Update on Thursday, November 5, 2020
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial
Tickers ADAP
From GlobeNewswire News Releases
Promising Data from Phase 1 Trial with ADP-A2AFP in Liver Cancer at the International Liver Congress Confirm Safety Profile and Demonstrate Potential Benefit for Patients
From GlobeNewswire News Releases
Adaptimmune Reports Q2 Financial Results and Business Update
From GlobeNewswire News Releases
Adaptimmune Granted Access to PRIority MEdicines (PRIME) Regulatory Support by the European Medicines Agency for ADP-A2M4 for the Treatment of Synovial Sarcoma
From GlobeNewswire News Releases
Adaptimmune to Report Q2 Financial Results and Business Update on Thursday, August 6, 2020
From GlobeNewswire News Releases
Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares
From GlobeNewswire News Releases
Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares
From GlobeNewswire News Releases
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
From GlobeNewswire News Releases
SPEAR T-cells Targeting MAGE-A4 Demonstrate New Responses in Esophagogastric Junction (EGJ), Lung, and Head and Neck Cancers – Late Stage Development Initiated in EGJ Cancer
From GlobeNewswire News Releases
Adaptimmune Reports Q1 Financial Results
From GlobeNewswire News Releases
SPEAR T-cells Derived from Stem-Cells Kill Cancer Targets - Adaptimmune Presents Advances from its Allogeneic Platform at ASGCT Annual Meeting
From GlobeNewswire News Releases
Adaptimmune to Report Q1 Financial Results on Thursday, May 14, 2020
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.